Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab

Abstract

Fig. 1. Haematoma and petechiae on both lower legs, which had developed after dupilumab therapy.

Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP

“…To our knowledge, no cases of thrombocytopenia or related medullary aplasia are reported in literature, neither for the use of dupilumab for other clinical indications [28,29]. A case report talks about an immune thrombocytopenic purpura in a patient with atopic dermatitis treated with dupilumab: the correlation was explained with a combination of nasopharyngitis, cefuroxime intake and reversion of a Th1/Th2 imbalance by dupilumab as possible trigger factors for immune thrombocytopenic purpura [30]. Anyway, our patient did not get an immune disorder, but rather a medullary disfunction which did not seem related to dupilumab intake.…”

Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab

“…The former may be non-inflammatory purpura caused by thrombocytopaenia or dysfunction, which is caused by direct toxicity of drugs or allergic reaction, and is involved in type II allergic reaction. The first case of immune thrombocytopaenic purpura caused by dupilumab was reported in 2019 ( 8 ). The latter may be caused by the direct effect of drug toxicity on capillaries, causing damage and purpura, which is involved in type III allergy, but has not reached vascular necrosis, and may be the early manifestation of vasculitis drug eruption ( 7 ).…”